Avidity Biosciences Raises $600 Million to Fund Late-Stage Pipeline and Commercial Expansion

Avidity Biosciences has completed a $600 million equity raise to fund its late-stage pipeline, including Duchenne muscular dystrophy therapy delpacibart zotadirsen. The company plans to submit a Biologics License Application by the end of 2025. The recent funding boost has shifted focus from financial concerns to trial outcomes and regulatory approvals. However, trading volatility and upcoming share unlocks may impact shareholder sentiment. The company's share price is down 11.2%.

Avidity Biosciences (NASDAQ:RNA) has successfully completed a $600 million equity raise, aiming to fund its late-stage pipeline, including the Duchenne muscular dystrophy therapy delpacibart zotadirsen. This significant funding boost has shifted the company's focus from financial concerns to trial outcomes and regulatory approvals. Avidity Biosciences plans to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) by the end of 2025, seeking accelerated approval for the therapy.

The company's share price has seen a 11.2% decrease since the announcement. This decline could be attributed to market volatility and upcoming share unlocks, which may impact shareholder sentiment. Despite the recent setback, Avidity Biosciences continues to make progress in its clinical trials and has received strong support from financial analysts.

In the second quarter of 2025, Avidity Biosciences reported significant growth in collaboration revenue, growing by 88.12% to reach $3.85 billion. The company's stock has been recommended as one of the best to buy for the next three months by Cantor Fitzgerald, with a price target of $96 Cantor Fitzgerald Reiterates a Buy Rating on Avidity Biosciences (RNA)^[2].

Avidity Biosciences' stock price volatility and upcoming share unlocks may present challenges for shareholders. However, the company's progress in clinical trials and regulatory approvals, coupled with strong financial performance, indicates a promising future for the biopharmaceutical company.